# Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

> **NCT03883113** · PHASE2 · COMPLETED · sponsor: **Barinthus Biotherapeutics** · enrollment: 145 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MVA-NP+M1
- **BIOLOGICAL:** Saline
- **BIOLOGICAL:** H3N2 (A/Belgium/2417/2015)

## Key facts

- **NCT ID:** NCT03883113
- **Lead sponsor:** Barinthus Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2019-12-16
- **Final completion:** 2020-04-17
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883113, "Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03883113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*